(Q33585560)

English

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

28 July 2017

multicenter clinical trial

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Kohei Kaku

1

1 reference

Europe PubMed Central

28 July 2017

Mads Frederik Rasmussen

2

1 reference

Europe PubMed Central

28 July 2017

Tomoyuki Nishida

3

1 reference

Europe PubMed Central

28 July 2017

Yutaka Seino

4

1 reference

Europe PubMed Central

28 July 2017

publication date

1 November 2011

1 reference

Europe PubMed Central

28 July 2017

Journal of Diabetes Investigation

1 reference

Europe PubMed Central

28 July 2017

2

1 reference

Europe PubMed Central

28 July 2017

6

1 reference

Europe PubMed Central

28 July 2017

441-447

1 reference

Europe PubMed Central

28 July 2017

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Hypoglycemia in diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

21 June 2018

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00128.X

21 January 2018

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014903

31 October 2018

Identifiers

10.1111/J.2040-1124.2011.00128.X

1 reference

Europe PubMed Central

28 July 2017

release_qajrkiqkezfeljl6wjutfobglq

1 reference

https://api.fatcat.wiki/v0/release/qajrkiqkezfeljl6wjutfobglq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33585560&oldid=1979563532"